Products
Zubotamig Biosimilar Bispecific Antibody (B7-H4 × CD3) for Research
Cat No.: GMP-Bios-INN-1479
Anti-VTCN1/B7H4 therapeutic antibody (Pre-made Zubotamig biosimilar,Bispecific mAb ((H-gamma1_L-kappa)_(H-gamma1_Llambda2))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zubotamig (development code GEN-1047) is a bispecific monoclonal antibody targeting B7-H4 (VTCN1). It is developed by Genmab for Solid tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1479-1mg | 1mg | |
| GMP-Bios-INN-1479-10mg | 10mg | |
| GMP-Bios-INN-1479-100mg | 100mg | |
| GMP-Bios-INN-1479-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zubotamig biosimilar, Bispecific mAb ((H-gamma1_L-kappa)_(H-gamma1_Llambda2)), Anti-VTCN1/B7H4;CD3E Antibody: Anti-B7‑H4/B7-H4/VTCN1/V-set domain-containing T-cell activation inhibitor 1 therapeutic antibody |
| INN Name | Zubotamig |
| Target | VTCN1/B7H4;CD3E |
| Format | Bispecific mAb ((H-gamma1_L-kappa)_(H-gamma1_Llambda2)) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Genmab |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
